Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

INTRODUCTION: Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl auristatin F (MMAF), to myeloma...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ophthalmol Ther
Egile Nagusiak: Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, Colby, Kathryn
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7708586/
https://ncbi.nlm.nih.gov/pubmed/32712806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40123-020-00280-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak